Search

Your search keyword '"Scagliotti, Giorgio"' showing total 1,689 results

Search Constraints

Start Over You searched for: Author "Scagliotti, Giorgio" Remove constraint Author: "Scagliotti, Giorgio"
1,689 results on '"Scagliotti, Giorgio"'

Search Results

1. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

2. Correction: TFEB controls sensitivity to chemotherapy and immuno-killing in non-small cell lung cancer

3. TFEB controls sensitivity to chemotherapy and immuno-killing in non-small cell lung cancer

4. Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.

5. Hormonal Agents in Localized and Advanced Prostate Cancer: Current Use and Future Perspectives

7. Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity

8. Actionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA)

9. The International Association for the Study of Lung Cancer Early Lung Imaging Confederation Open-Source Deep Learning and Quantitative Measurement Initiative

10. Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial

13. Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1

17. Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy.

19. Detection of ALK fusion variants by RNA-based NGS and clinical outcome correlation in NSCLC patients treated with ALK-TKI sequences

23. Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study

24. A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma

25. The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015

26. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study

27. Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of Immunotherapy.

28. SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma

29. Supplementary Figure S4 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade

30. Data from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade

31. Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial

32. Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer

33. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial

38. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

39. The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer

42. Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic

43. Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations

44. IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy

45. New Approaches to SCLC Therapy: From the Laboratory to the Clinic

48. Quality of life assessment and reporting in colorectal cancer: A systematic review of phase III trials published between 2012 and 2018

49. Supplementary Figure 3 from Niraparib plus Dostarlimab in Pleural Mesothelioma or Non–Small Cell Lung Cancer Harboring HRR Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial

Catalog

Books, media, physical & digital resources